You are here:
LinkedIn-button

About us

Company
profile

Even the most promising vaccines don’t always make it out of the laboratory into large-scale production. We at Intravacc are fully aware of the challenges on the long road of vaccine development. We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies.

The Netherlands-based Intravacc part of the Utrecht Science Park location Bilthoven. is one of the world’s leading organizations with many years of experience in translational vaccinology. As an established independent clinical development and manufacturing organization (CDMO) in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials in humans.

LEARN MOREANNUAL REPORT 2020
LinkedIn-button

Our Vision

To reduce human diseases through innovative vaccine technology

LinkedIn-button

Our Mission

To partner with governmental
agencies, NGO's and private entities
to help to reduce the burden of diseases

LinkedIn-button

Intravacc to the point

  • Founded in 2013
  • HQ at Utrecht Science Park Bilthoven
  • Experts in vaccinology
  • Clinical development & manufacturing organization
  • 2000+ m2 state-of the art facilities, incl BSL-2/3 & GMP
  • ISO 9001 and ISO 14001 certified
  • >140 high qualified employees
  • 50+ customers worldwide
  • 300+ scientific publications in peer reviewed journals
LinkedIn-button

About us

Certifications

Intravacc performs her activities in compliance with applicable laws and regulations. To support the customers expectations in the most efficient way, the quality management system is in compliance with ISO9001.

The care for employees and for the environment is a top priority for Intravacc. Sustainability is important to guarantee a safe and health environment for the future. Therefore, Intravacc implemented an environmental management system according to ISO14001.
An external company regularly audits the management systems for ISO9001 and ISO14001 to assure continuously compliance.

For the manufacturing and quality control of clinical trial materials, Intravacc B.V. has a manufacturing license granted by the Dutch Authorities. Regular inspections are performed by the Dutch Inspectorate of Health to verify compliance.

ISO 9001 certificate
ISO 14001 certificate
GMP manufacturer’s license
LinkedIn-button

About us

Latest News

Intravacc launches hybrid business model to drive innovation and growth

Intravacc launches hybrid business model to drive innovation and growth Bilthoven, the Netherlands, 16 September 2021 – Intravacc, a global leader in translational research and the development of vaccines against infectious diseases and therapeutic vaccines, today launches its new hybrid business model that should lead to further innovation and sustainable growth over the next five…

  • Hybrid model: CDMO services and development of a proprietary vaccine pipeline
  • Intravacc will also put emphasis on the therapeutic vaccine market
  • Intravacc’s proprietary vaccine portfolio will mainly focus on intranasal administration
  • Intravacc launches promotional campaign, supporting the funding of a phase I clinical trial with the Avacc 10 nasal spray vaccine
Read more

Intravacc’s inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China

Intravacc’s inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China Bilthoven, the Netherlands, 20 July 2021 – Intravacc, a world leader in translational research and development of vaccines for infectious diseases and therapeutics, today announced that the Chinese National Medical Products Administration (NMPA)  formally known as the Chinese FDA, granted Sinovac Biotech…

  • Sabin-IPV polio vaccine developed by Intravacc contributes to the eradication of polio
  • Sinovac’s polio vaccine (sIPV) receives market authorization from the NMPA in China
  • Intravacc’s cell technology also used for the development of Sinovac’s Covid-19 vaccine that was introduced on the market recently and is currently under rolling review by EMA
Read more

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine Bilthoven, the Netherlands, 13 April 2021 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive preclinical data for its OMV based Lyme disease vaccine. Publication of this study in the peer reviewed scientific journal Vaccine titled “Vaccination…

  • Neisserial OMV based Lyme vaccine elicit high antibody titers in mice
  • Two conventional vaccines based on Intravacc's OMV platform and VEO cell platform
Read more
LinkedIn-button

About us

Media

LinkedIn-button

About us

Join our Community

Are you interested in becoming part of an innovative community, to learn alongside top scientists, to work with state-of-the art equipment, to get an inside look of and contribute to the biotech sector, where industry leaders, government, universities and international non-governmental organizations collaborate? Then Intravacc is the place for you.

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.